Abstract
Background: The aim of this study is to explore the efficacy and safety of ulinastatin for the treatment of patients with severe acute pancreatitis (SAP).

Methods: We will search randomized controlled trials which assess the efficacy and safety of ulinastatin for patients with SAP from the electronic databases of Cochrane Library, MEDILINE, EMBASE, CINAHL, PsycINFO, Scopus, CBM, Wangfang, VIP, and CNKI. All electronic databases will be searched from inception to the present with no limitations of language and publication status. Two researchers will carry out study selection, data extraction, and study quality assessment independently. Another researcher will help to resolve any disagreements between 2 researchers.

Results: The outcomes include overall mortality, time of hospital stay, complications of systemic or local infection, multiple organ deficiency syndrome, health related quality of life (as measured as the 36-Item Short Form Health Survey), and adverse events related to nutrition.

Conclusion: This study will provide evidence to evaluate the efficacy and safety of ulinastatin in the treatment of patients with SAP.

Systematic review registration: PROSPERO CRD42019149566.

Abbreviations: CIs = confidence intervals, RCTs = randomized controlled trials, SAP = severe acute pancreatitis.

Keywords: efficacy, safety, severe acute pancreatitis, ulinastatin

1. Introduction

Severe acute pancreatitis (SAP) is one of the most devastating diseases at the emergency clinical practice.\(^{[1-3]}\) It is characterized as an acute abdominal disease with a local pancreatic damage.\(^{[4-6]}\) It often quickly spreads into multiple organ dysfunction.\(^{[7-8]}\) Such condition is often associated with high morbidity and mortality.\(^{[9-10]}\) It has been estimated that its mortality rate still varies from 10% to 85% according to the various studies, although there is a decreasing tendency over the last decade.\(^{[11-17]}\) A variety of previous clinical studies have reported to use ulinastatin for the treatment of patients with SAP.\(^{[18-23]}\) However, no systematic review and meta-analysis has investigated the efficacy and safety of ulinastatin for the treatment of patients with SAP. Thus, this study will firstly assess the efficacy and safety of ulinastatin for treating SAP systematically.

This study has supported by the Yan’an Science and Technology Huimin Project (2016-HM-08-01). The funder did not involve any parts of this study. The authors report no conflicts of interest.

* Department of Critical Care Medicine, Yulin No.1 Hospital, Yulin, China.

† Correspondence: Wei-min Li, Department of Emergency, Yulin No.1 Hospital, No.93, Yuxi Avenue, Gaoxin District, Yulin 719000, Shaanxi, China (e-mail: weiml2001@outlook.com).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite this article: Yao Jh, Li Wm. Efficacy of ulinastatin for the treatment of patients with severe acute pancreatitis. Medicine 2019;98:43(e17644).

2. Methods

2.1. Dissemination and ethics

This study is expected to be published at peer-reviewed journals. Ethical approval is not needed, because all data in this study has been published.

2.2. Study registration

This study protocol has been registered on PROSPERO CRD42019149566. We report the results of this study according to the Cochrane Handbook for Systematic Reviews of Interventions and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol statement guidelines.\(^{[24]}\)

2.3. Inclusion criteria for study selection

2.3.1. Types of studies. We will include randomized controlled trials (RCTs) of ulinastatin for the treatment of patients with SAP without language limitation. However, non-clinical studies, case studies, observational studies, and non-RCTs will be excluded.

2.3.2. Types of participants. Patients diagnosed with SAP will be considered for inclusion, while ethnicity, gender, and age are not limited.

2.3.3. Types of interventions. The treatment group has utilized the ulinastatin without restrictions of dose and frequency. The control group has received any interventions, such as placebo, except any forms of ulinastatin.

2.3.4. Type of outcome measurements. The outcome measurements consist of overall mortality, time of hospital stay, complications of systemic or local infection, multiple organ...
deficiency syndrome, health related quality of life (as measured as the 36-Item Short Form Health Survey), and adverse events related to nutrition.

2.4. Search methods for the identification of studies

2.4.1. Electronic database searches. Literature records will consist of electronic databases and manual searches. We will search Cochrane Library, MEDLINE, EMBASE, CINAHL, PsycINFO, Scopus, CBM, Wangfang, VIP, and CNKI. All electronic databases will be searched from inception to the present without restrictions of language and publication status. All RCTs of ulinastatin in the treatment of patients with SAP will be considered. The search strategy example for Cochrane Library is presented in Table 1. Similar search strategies of other electronic databases will also be used.

2.4.2. Search for other resources. Aside from all electronic databases, dissertations, conference proceedings, ongoing studies, clinical registry, and reference list of included studies will be searched.

2.5. Data collection and analysis

2.5.1. Study selection. Two researchers will independently read the titles and abstracts of searched literature records to exclude irrelevant records. We will also read the full texts of remaining studies to determine whether those studies can be finally included. Any divergences regarding the study selection between 2 researchers will be solved by a third researcher. We will present the study selection process in the flow chart in Figure 1.

2.5.2. Data collection and management. Two researchers will retrieve the following information independently according to the pre-designed data extraction sheet. If there is a disagreement, another researcher will be involved to solve such divergence. The extracted information include study details (title, first author, year of publication, et al), patient details (baseline characteristics, diagnostic criteria, inclusion and exclusion criteria, et al), study methods (sample size, randomization, blind, concealment, et al), treatment details (dose, frequency, duration, etc), and outcomes (outcome measurements, safety, et al).

2.5.3. Risk of bias assessment. Two researchers will evaluate each included study independently with Cochrane Handbook for Systematic Reviews of Interventions tool. This tool covers 7 aspects, and each 1 is further classified into high, unclear or low risk of bias. Another researcher will help to resolve any disagreements between 2 researchers.

2.5.4. Measurement of treatment effect. For enumeration data, we will record the risk ratio and 95% confidence intervals, while for continuous data, we will record the mean difference or standardized mean difference and 95% confidence intervals.

2.5.5. Dealing with missing data. If there is missing or insufficient data, we will contact primary authors to require it. If it is not obtained, we will synthesize and analyze the available data, and will also discuss the possible impacts of the missing data.

2.5.6. Assessment of heterogeneity. Heterogeneity among eligible studies will be identified by $I^2$ test. When $I^2 \leq 50\%$, heterogeneity is reasonable, while when $I^2 > 50\%$, the heterogeneity is considered as substantial.

2.5.7. Data synthesis. We will utilize RevMan 5.3 software for statistical analysis. A fixed-effects model will be used, and data will be synthesized if low heterogeneity exists among included studies ($I^2 \leq 50\%$). We will carry out meta-analysis if there are more than 2 studies on the same interventions, and outcome measurements. On the other hand, a random-effect model will be utilized, and subgroup analysis will be conducted if there is significant heterogeneity among included studies ($I^2 > 50\%$). In addition, meta-regression test will be performed.

2.5.8. Publication bias. We will apply Funnel plot and Egger regression test to identify publication bias if there are more than 10 eligible studies.\(^{[25]}\)

2.5.9. Subgroup analysis. We will investigate the source of heterogeneity using subgroup analysis based on different interventions, controls, and outcomes.

2.5.10. Sensitivity analysis. We will conduct sensitivity analysis to examine the robustness and satiability of outcome results by removing studies with high risk of bias.

3. Discussion

Previous studies have reported that ulinastatin is efficacious in the treatment of patients with SAP. However, its conclusion is still inconsistent. Thus, this study will provide a detailed summary of the efficacy and safety of ulinastatin compared to other comparators in the treatment of SAP based on the present

### Table 1

| Number | Search terms |
|--------|--------------|
| 1      | Mesh descriptor: (pancreatitis) explode all trees |
| 2      | Mesh descriptor: (pancreatitis, acute) explode all trees |
| 3      | Mesh descriptor: (pancreatitis, multiple organ dysfunction syndrome) explode all trees |
| 4      | Or (severe acute pancreatitis\({}^\star\)) or (SAP\({}^\star\)) or (pancreatitis, acute necrotizing\({}^\star\)) or (necrotizing pancreatitis, acute\({}^\star\)) or (acute necrotizing pancreatitis\({}^\star\)) or (glycoprotein\({}^\star\)) or (acid-resistant protease inhibitor\({}^\star\)) |
| 5      | Or 1–4 |
| 6      | (ulinastatin) explode all trees |
| 7      | Or (Miracid\({}^\star\)) or (U-IV\({}^\star\)) or (Bikunin\({}^\star\)) or (urinary trypsin inhibitor\({}^\star\)) or (glycoprotein\({}^\star\)) or (acid-resistant protease inhibitor\({}^\star\)) |
| 8      | Or 6–7 |
| 9      | Mesh descriptor: (randomized controlled trials) explode all trees |
| 10     | Or (random\({}^\star\)) or (randomly\({}^\star\)) or (allocation\({}^\star\)) or (concealment\({}^\star\)) or (blind\({}^\star\)) or (placebo\({}^\star\)) or (clinical trials\({}^\star\)) or (controlled trials\({}^\star\)) |
| 11     | Or 9 and 10 |
| 12     | Or 5 and 8 and 11 |
evidence, and to assess the clinical efficacy of ulinastatin. The results of this study will provide comprehensively assessment on the efficacy and safety of ulinastatin for treating patients with SAP, and will provide helpful evidence for the clinical practice and future studies.

**Author contributions**

Conceptualization: Jian-hui Yao, Wei-min Li.
Data curation: Jian-hui Yao, Wei-min Li.
Formal analysis: Jian-hui Yao.
Investigation: Wei-min Li.
Methodology: Jian-hui Yao.
Project administration: Wei-min Li.
Resources: Jian-hui Yao.
Software: Jian-hui Yao.
Supervision: Wei-min Li.
Validation: Jian-hui Yao, Wei-min Li.
Visualization: Jian-hui Yao, Wei-min Li.

Writing – original draft: Jian-hui Yao, Wei-min Li.
Writing – review & editing: Jian-hui Yao, Wei-min Li.

**References**

[1] Warren M, McCarthy MS, Roberts PR. Practical application of the revised guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: a case study approach. Nutr Clin Pract 2016;31:334–41.
[2] Leppäniemi A, Tolonen M, Tarasconi A, et al. 2019 WSES guidelines for the management of severe acute pancreatitis. World J Emerg Surg 2019;14:27.
[3] Huang Z, Tang L. Diagnosis and treatment of peripancreatic infection in severe acute pancreatitis. Zhonghua Wei Chang Wai Ke Za Zhi 2018;21:1361–5.
[4] Portelli M, Jones CD. Severe acute pancreatitis: pathogenesis, diagnosis and surgical management. Hepatobiliary Pancreat Dis Int 2017;16:155–9.
[5] Maheshwari R, Subramanian RM. Severe acute pancreatitis and necrotizing pancreatitis. Crit Care Clin 2016;32:279–90.
[6] Pezzilli R, Zerbi A, Campra D, et al. Consensus guidelines on severe acute pancreatitis. Italian Association for the Study of the Pancreas (AISP). Dig Liver Dis 2015;47:532–43.
[7] Zerem E. Treatment of severe acute pancreatitis and its complications. World J Gastroenterol 2014;20:13879–92.
[8] Wang CY, Zhao YP. The guidelines interpretation for diagnosis and treatment of severe acute pancreatitis. Zhonghua Wai Ke Za Zhi 2013;51:198–200.
[9] Bradley EL3rd, Dexter ND. Management of severe acute pancreatitis: a surgical odyssey. Ann Surg 2010;251:6–17.
[10] Beger HG, Rau B, I senmann R. Natural history of necrotizing pancreatitis. Pancreatology 2003;3:93–101.
[11] Munsell MA, Buscaglia JM. Acute pancreatitis. J Hosp Med 2010;5:241–50.
[12] Petrov MS, Shanbhag S, Chakraborty M, et al. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology 2010;139:813–20.
[13] van Baal MC, van Santvoort HC, Bollen TL, et al. Systematic review of percutaneous catheter drainage as primary treatment for necrotizing pancreatitis. Br J Surg 2011;98:18–27.
[14] Buter A, Imrie CW, Carter CR, et al. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002;89:298–302.
[15] Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, levpafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62–9.
[16] Beger HG, Rau BM. Severe acute pancreatitis: clinical course and management. World J Gastroenterol 2007;13:5043–51.
[17] Bruennler T, Langgattern J, Lang S, et al. Outcome of patients with acute, necrotizing pancreatitis requiring drainage does drainage size matter? World J Gastroenterol 2008;14:725–30.
[18] Zhao L, Li X, Shi Z. Clinical observation on severe acute pancreatitis treated with electroacupuncture at Dachangshu (BL 25) and Shangjiuxu (ST 37) combined with ulinastatin. Zhonghua Zhen Jiu 2018;38:132–6.
[19] Wang J, Jin J, Huang J, et al. Clinical value of the early use of ulinastatin in patients with moderately severe or severe acute pancreatitis. Zhonghua Yi Xue Za Zhi 2017;97:1252–5.
[20] Wang G, Liu Y, Zhou SF, et al. Effect of somatostatin, ulinastatin and gabexate on the treatment of severe acute Pancreatitis. Am J Med Sci 2016;351:506–12.
[21] Guo H, Chen J, Suo D. Clinical efficacy and safety of ulinastatin plus octreotide for patients with severe acute pancreatitis. Zhonghua Yi Xue Za Zhi 2015;95:1471–4.
[22] Abraham P, Rodrigues J, Mouldick N, et al. Efficacy and safety of intravenous ulinastatin versus placebo along with standard supportive care in subjects with mild or severe acute pancreatitis. J Assoc Physicians India 2013;61:535–8.
[23] Wang G, Wen J, Wilbur RR, et al. The effect of somatostatin, ulinastatin and Salvia miltiorrhiza on severe acute pancreatitis treatment. Am J Med Sci 2013;346:371–6.
[24] Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[25] Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.